Summary of achievements
2014–2021
63 countries participate in EDCTP-funded activities:

19 European countries and 44 African countries

EDCTP investments in R&D

- Clinical studies: €684.50 M to support 140 collaborative research projects with large-scale clinical trials and other clinical research activities conducted by European-African consortia.
- Clinical research capacity: €85.47 M to support 90 projects that strengthen the enabling environment for conducting clinical trials and clinical research.
- Fellowship programme: €44.48 M to support 205 fellowships projects that focus on the career development of African scientists.

Total funding €814.45 M for 435 projects awarded to date.

Investments in calls for proposals

2020: €94.08 M to €814.45 M
2019: €112.14 M to €720.37 M
2018: €164.19 M to €608.23 M
2017: €188.14 M to €444.04 M
2016: €155.63 M to €255.90 M
2015: €83.42 M to €100.27 M
2014: €16.85 M

Indicative amounts based on signed grant agreements and proposals approved for funding
Medical interventions

Collaborative research projects by disease

- Tuberculosis, 33 grants:
  - €194.83 M
- Malaria, 17 grants:
  - €136.47 M
- HIV & HIV-associated infections, 20 grants:
  - €113.05 M
- Emerging diseases, 37 grants:
  - €77.61 M
- Neglected infectious diseases, 19 grants:
  - €70.60 M
- Diarrhoeal diseases, 6 grants:
  - €51.19 M
- Lower respiratory tract infections, 8 grants:
  - €40.75 M

Collaborative research projects by intervention

- Drugs, 51 grants:
  - €282.01 M
- Vaccines, 26 grants:
  - €243.05 M
- Diagnostics, 47 grants:
  - €121.32 M
- Non-intervention specific topics, 9 grants:
  - €31.90 M
- Product-focused implementation research, 7 grants:
  - €6.22 M

332 is the total number of clinical studies awarded by EDCTP since 2014. Of these, 64% (213) are interventional (clinical trials) studies of drugs and vaccines, diagnostic testing and evaluation studies, and 36% (119) are non-interventional studies (observational studies of drugs and vaccines, diagnostics and prognostics, and other studies).

Research centres and clinical trial sites involved in clinical research

38 sub-Saharan African countries host recruitment sites of EDCTP-funded collaborative clinical studies.

63% (91) of the clinical trials are phase II and III studies of drugs and vaccines aiming to deliver key evidence on safety and efficacy. The phase III trials also aim to provide data to support product registration.

Clinical trials of drugs and vaccines by phase

16% (23) of the trials involve post-license (phase IV) studies aiming to influence health policies and practice, and optimise the delivery of medical interventions for the wide-range of sub-Saharan African health systems and diverse populations.

Population in clinical studies

12% (37) of all studies target pregnant women and their children. Other key populations are also involved in the studies, such as newborns and infants (77; 25%), children (103; 33%) and adolescents (102; 33%).
Collaboration and capacity development

EDCTP projects involve 308 sub-Saharan African institutions. These account for 60% of total EDCTP funding.

EDCTP’s contribution towards strengthening ethics and regulatory capacity in Africa

37 sub-Saharan African countries have been awarded EDCTP funding for the establishment of functional regulatory systems and capacities for ethical review of clinical research.

18 sub-Saharan African countries are members of the EDCTP Association. In the EDCTP 2014-2020 work plans, 16 members have submitted 120 Participating States’ initiated Activities (PSIAs) of total committed value of €67 M.
205 fellows from 24 African countries are supported with the potential to become research leaders. Furthermore, EDCTP has supported 580 trainees on EDCTP projects from 33 sub-Saharan African countries (including 217 Master’s and 229 PhD students).

Of the academic trainings (Bachelor’s, Master’s and PhD) of African researchers, 78% are pursued at academic institutions in Africa.

150 epidemiologists and biostatisticians across Africa funded through an EDCTP-Africa CDC joint initiative.

37% of the projects in the EDCTP2 portfolio are led by a female:

46% of the 580 African academic trainees are female.

39% of the members of expert review committees for EDCTP calls evaluations are female.
14 European countries are members of the EDCTP Association. In the EDCTP 2014-2020 work plans, these members have submitted 301 Participating States’ Initiated Activities (PSIAs) of total committed value of €1.157 billion. PSIAs are research activities within the scope of the EDCTP programme that are funded and implemented by one or more member countries.

€186.77 M is the total cash received from the European member countries to the EDCTP programme.

15% (338 out of 2231) of all participations in EDCTP-funded projects involve private-sector institutions. They include private not-for-profit entities (245 or 11%) such as foundations and product development partnerships, private-for-profit institutions (29 or 1%) such as pharmaceutical companies and small-and-medium enterprises (64 or 3%).

Private sector institutions were awarded €176.30 M by EDCTP in 2021.

€26.84 M has been leveraged from partners for the launch of joint or coordinated calls for proposals.

Partner contributions to joint initiatives launched with EDCTP

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coalition for Epidemic Preparedness Innovations (CEPI)</td>
<td>€10 M</td>
</tr>
<tr>
<td>WHO/TDR</td>
<td>€5 M</td>
</tr>
<tr>
<td>EFPIA members</td>
<td>€2.55 M</td>
</tr>
<tr>
<td>Fundación Mundo Sano-España</td>
<td>€2 M</td>
</tr>
<tr>
<td>Novartis International AG</td>
<td>€1.67 M</td>
</tr>
<tr>
<td>Fondation Botnar</td>
<td>€1.62 M</td>
</tr>
<tr>
<td>African Research Excellence Fund (AREF)</td>
<td>€1.22 M</td>
</tr>
<tr>
<td>Botnar Research Centre for Child Health (BRCCH)</td>
<td>€0.86 M</td>
</tr>
<tr>
<td>GlaxoSmithKline (GSK)</td>
<td>€0.55 M</td>
</tr>
<tr>
<td>Switzerland</td>
<td>€0.50 M</td>
</tr>
<tr>
<td>Calouste Gulbenkian Foundation</td>
<td>€0.47 M</td>
</tr>
<tr>
<td>Leprosy Research Initiative (LRI)</td>
<td>€0.40 M</td>
</tr>
</tbody>
</table>

€373.95 M has been leveraged as co-funding to EDCTP projects through the EDCTP strategic calls for proposals (€271.58 M in cash and €102.37 M in-kind).

Co-funding in EDCTP projects (top 5 funders)

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute of Health (NIH), USA</td>
<td>€106.32 M</td>
</tr>
<tr>
<td>President’s Emergency Fund for AIDS Relief, USA</td>
<td>€50 M</td>
</tr>
<tr>
<td>Bill &amp; Melinda Gates Foundation, USA</td>
<td>€49.73 M</td>
</tr>
<tr>
<td>TB Alliance, USA</td>
<td>€20.40 M</td>
</tr>
<tr>
<td>Medicines for Malaria Venture (MMV), Switzerland</td>
<td>€19.90 M</td>
</tr>
</tbody>
</table>